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ABSTRACT 
Background. Cell-free DNA (CFDNA) in the plasma/serum of patients with cancer 
demonstrates tumour-associated genetic alterations, offering possibilities for 
diagnosis, prognostication and disease monitoring.  There is wide variation in the 
reported levels of CFDNA, associated with different methods used to collect, process 
and analyse blood samples.  We therefore evaluated different aspects of laboratory 
protocols for the processing and purification of CFDNA in clinical studies. 
 
Methods. We evaluated and compared the QIAamp kit and a Triton/Heat/Phenol 
protocol (THP) for CFDNA purification. Total CFDNA was quantified by PicoGreen 
assay and SYBR green real-time PCR assay was used to amplify specific genes to 
estimate the efficiency of different protocols.   
 
Results. The efficiency of DNA extraction was 18.6% using the standard QIAamp 
protocol and 38.7% using the THP method (p < 0.0001, unpaired t-test). A modified 
QIAamp protocol that included a proteinase incubation stage and elution volumes up 
to 300 ml increased DNA yields, but was not as good as the THP method.  
 
Conclusions. Blood samples should be kept at/or below room temperature (18oC-
22oC) for no more than 2 hours before plasma separation by double-spin. Because of 
its higher efficiency, low-cost and good quality products, the THP protocol is 
preferred for extraction of CFDNA. 
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INTRODUCTION 
Cell-free circulating DNA (CFDNA) has been studied in a wide range of physiological 
and pathological conditions, including pregnancy, trauma, inflammatory disorders 
and malignancy [1, 2]. It is present in normal healthy individuals at low concentrations 
(ng/ml) [3]. Raised levels of CFDNA in cancer patients have been reported in many 
tunour types [2-5]. The finding that genetic and epigenetic changes typical of tumours 
can be detected in CFDNA from cancer patients, suggests that the excess CFDNA is 
of tumour origin. Although the precise mechanism of DNA release into the blood 
remains uncertain, it probably derives from a combination of apoptosis, necrosis and 
active release from tumour cells [6]. Such cell-free DNA has shown promise for 
improving early clinical diagnosis, prognostication and disease monitoring in 
inaccessible tumour types, such as lung cancer [7-11].  
 
Although higher levels of CFDNA are consistently reported in cancer patients than 
healthy controls, there is considerable variation between studies. This may be 
attributable to differences in study design including selection of patient and control 
groups, and the methods used to extract and quantify CFDNA [10, 12-14]. No agreed 
standards exist, and many publications fail to specify how samples were obtained, 
processed and analysed. The problems of prolonged sample storage have been 
highlighted by a recent report that DNA levels in plasma stored at –80oC declined by 
30% per year [15]. Thus, this study was designed to evaluate the factors most likely 
to influence the yield of CFDNA from clinical samples. 
 
Various methods have been used to purify CFDNA, including using modified salting-
out [16], chromatography resins [16, 17], magnetic beads [18], or guanidium 
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thiocyanate [19]. The most popular is the QIAamp blood kit, which binds DNA to a 
silica-gel membrane, providing a fast and easy way to purify total DNA for 
polymerase chain reaction (PCR) analysis. We found that the recovery of CFDNA 
was less than 20% using the QIAamp DNA Midi Kit. Some authors have 
recommended using a predigestive buffer in plasma/serum samples to improve the 
results [16, 18, 20]. Therefore, we have evaluated standard and modified QIAamp 
protocols and compared them with a simple Triton/Heat/Phenol (THP) protocol. 
Because DNA is present in plasma/serum at such low concentrations (ng/ml), it is 
crucial to optimize laboratory protocols for the processing and extraction of CFDNA. 
 
MATERIALS AND METHODS 
Sample collection and preparation 
To compare different CFDNA extraction protocols, commercial pooled human serum 
(SLI Ltd, UK) was spiked with reference genomic DNA (Sigma-Aldrich, UK) or a 
known amount of linearised bcl-2 plasmid reference DNA (final concentration in 
serum: 0, 50 and 100 ng/ml). For clinical samples, 20 ml peripheral blood was 
collected from healthy volunteers into EDTA tubes [21]. Plasma was separated by 
double centrifugation (800g for 10 min, separation, and 1600g for 10 min). Plasma 
aliquots were immediately frozen at –70oC.  
 
CFDNA extraction 
For the standard QIAamp method, DNA was purified using the QIAamp Blood DNA 
Midi Kit (Qiagen, UK) in accordance with the manufacturer’s instructions.  The 
protocol was also modified by incubating samples at 37oC for 2 hours with 400 mg/L 
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proteinase K instead of the protease provided in the kit, and eluting the DNA with 
different volumes of elution buffer.  
 
For the THP method, 500 μl of plasma/serum was mixed with 5 μl Triton X-100 
(Sigma-Aldrich, UK) and heat denatured at 98oC for 5 minutes. Samples were placed 
on ice for 5 minutes, then extracted with an equal volume of phenol-chloroform-
isoamyl alcohol (25:24:1, v:v:v) (Sigma-Aldrich, UK) and centrifuged for 10 minutes at 
14,000 g. The aqueous phase was precipitated overnight with 1/10 volume of 3M 
NaOAc and 2.5 volume of 100% ethanol at –20oC. The DNA pellet was washed with 
ethanol, air-dried and resuspended in 50 μl of ddH2O.  
 
The quality of the purified DNA was checked by conventional PCR amplification of 
the p53 gene. To determine if the different DNA extraction methods led to loss of 
small DNA fragments, the Quick-Load® 100 bp DNA Ladder (New England Biolabs, 
UK) was spiked into pooled human serum. After re-purification, the ladder DNA was 
analyzed on 1.5% agarose gels with 0.5 mg/ml ethidium bromide. 
  
Quantitative analysis of DNA  
Quantification of total DNA was performed using the PicoGreen assay (Molecular 
Probes, Netherlands) following the manufacturer’s instructions. Genomic (hGAPDH) 
[22] and plasmid (bcl-2) DNA were analyzed by SYBR-Green I fluorescence real-time 
PCR with an ABI7900 Sequence Detection Instrument (Applied Biosystems, USA). 
Melting curves of all tubes were observed for every reaction to ensure that only one 
product was present. All samples were performed in triplicate and the mean value 
was used for quantification. The qPCR efficiency was calculated from the slope of the 
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standard curve (equation: efficiency = 10(-1/slope)-1) and all correlation coefficients (r2) 
were above 0.99.   
  
Statistical analysis 
Quantitative results were presented as mean ± standard deviation (SD). Differences 
were evaluated by two-tailed unpaired t-test (p-value) and correlations were 
evaluated using the Pearson correlation coefficient (r). The reproducibility of different 
protocols was evaluated by coefficient of variation (CV). The effects of time delay 
during blood sample processing on CFDNA concentration were analyzed by two-way 
ANOVA with interaction. GraphPad Prism 4.03 software was used for statistical 
analysis. 
 
RESULTS  
Optimization of QIAamp protocol 
Digesting or denaturing the plasma/serum proteins is one of the most important 
stages during the extraction of CFDNA. We compared the protease provided in the 
QIAamp Blood Kit with proteinase K for the purification of low quantities of CFDNA. 
Figure 1 shows that pre-incubation of serum samples with proteinase K (400 µg/ml) 
at 37oC for 1 hour (Q37-1, P37-1) significantly increased the DNA recovery compared to 
no incubation (QN, PN) (QN vs Q37-1: p = 0.003; PN vs P37-1: p = 0.002) and there was 
significantly better DNA yield with proteinase K than the QIAgen protease (QN vs PN: 
p = 0.040). However, longer incubation time (2 hours) and incubation at 50oC [23] did 
not improve the DNA yield further (data not shown). 
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In the QIAamp midi Kit, use of 200 μl of elution buffer AE or ddH2O is recommended. 
Some groups have routinely used as little as 50 μl of elution buffer [24]. We studied 
the effects of different volumes, composition and temperature of elution buffer on 
CFDNA recovery (figure 2). Increasing volumes of elution buffer between 50 (A) and 
300 μl (D) led to significantly better DNA yield, but more than 300 μl did not further 
improve the recovery for 1 ml of initial serum sample. There was no significant 
difference in CFDNA yields with distilled water or AE buffer. Similarly, pre-warming 
the elution buffer at 37oC or 50oC did not significantly affect the CFDNA recovery (p = 
0.33). Further, we investigated whether CFDNA recovery could be improved by 
reloading samples onto the QIAamp columns. CFDNA recovery from serum did not 
change significantly (p = 0.27) when samples were reloaded. 
 
Evaluation of THP protocol for DNA extraction  
In our initial studies, the recovery of CFDNA from plasma or serum with the QIAamp 
Midi Kit was less than 20%. We therefore evaluated the simple THP protocol. Pooled 
human serum was spiked with different amounts of genomic DNA and heated at 
98oC for 5 minutes, then direct PCR was performed on 5 µl samples using primers 
for the p53 gene. The lowest spiked concentration was 25 ng/ml and generated 
positive products consistently. No significant improvement was achieved by using a 
different protein digestion buffer (data not shown). Phenol extraction was used to 
obtain purified DNA solution for further analysis requiring good-quality DNA 
templates. Since CFDNA exists in fragments of varying size and QIAGEN columns 
might lose small DNA fragments (<150bp) [20], we checked the ability of THP 
procedure to extract DNA fragments of different sizes. Figure 3A shows that 
fragments as small as 100bp were consistently obtained using THP method. It is 
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essential that DNA extraction methods used for CFDNA yield purified DNA of 
sufficient quality for PCR analysis. Figure 3B shows that DNA extracted using the 
THP protocol from human serum spiked with 50 ng/ml and 200 ng/ml genomic DNA 
was suitable for PCR amplification of the p53 gene.  
 
Comparison of the THP and standard QIAamp methods 
We compared CFDNA extracted by the THP and QIAamp standard protocols from 
pooled healthy human serum using qPCR for the hGAPDH gene. Whereas 15/15 
THP samples were successfully amplified, only 3/15 QIAamp samples were. The 
mean concentration of CFDNA obtained using the THP protocol was 4.73 ng/ml 
(range: 1.49 -10.25 ng/ml), while that for the QIAamp standard protocol was 1.67 
ng/ml (figure 4).  
 
To determine the efficiency and reproducibility of these two different protocols, we 
added linearized bcl-2 plasmid DNA (reference DNA) into pooled human serum to 
achieve a final concentration of 50 ng/ml, close to the average concentration of most 
reported CFDNA in cancer patients. The reference DNA was re-purified by the two 
different extraction methods in 20 replicate samples (figure 5). Whereas 20/20 THP 
samples were successfully amplified by the SYBR green real-time PCR quantitive 
assay, only 14/20 QIAamp samples were successfully amplified. Figure 5 shows that 
the efficiency of DNA extraction by the THP protocol (38.74±7.15%; mean±SD) was 
significantly better than that of the QIAamp protocol (18.63±4.34%; mean±SD; p < 
0.0001, unpaired t-test). The coefficients of variation were similar for the two 
protocols at 18.5% for THP and 23.3% for QIAamp.  In repeated experiments, 
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consistent results were obtained showing the efficiency of DNA extraction to be about 
20% for the QIAamp protocol and about 40% for the THP protocol. 
 
The effects of delays in blood processing and storage temperature 
To optimize the yield of low-level CFDNA from serum and plasma, we considered the 
effects of delays in blood processing and storage temperature prior to DNA 
extraction. Each blood sample from 3 different healthy donors was divided into twelve 
aliquots and left at room temperature (RT, 180C-200C) or on ice (at 0oC). Plasma 
separation and DNA extraction were processed at different time intervals after 
venepuncture using the THP protocol (figure 6). There was no significant difference 
in CFDNA yield for samples processed up to 2 hours after venepuncture, but after 
this (4-25 hours), the amount of recovered DNA increased. Two-way ANOVA showed 
the effect of time was considered extremely significant, but the temperature did not 
affect the CFDNA significantly. Time accounts for 70.4% of the total variance (F = 
15.80; P < 0.0001).  
 
DISCUSSION 
Published studies on CFDNA in cancer patients give remarkably little detail about the 
conditions under which clinical samples were obtained, transported, stored or 
processed, making comparisons of the reported results difficult. Very few studies 
have addressed the efficiency or reproducibility of their chosen DNA extraction 
methods. We were initially surprised to obtain DNA yields of less than 20%, but a 
detailed literature review showed that this was not unusual [16, 17]. There is clearly a 
need to optimize DNA extraction from clinical samples where it is present at such low 
levels. Very low amounts of CFDNA have been found in healthy individuals, although 
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some authors consider it undetectable in plasma [25]. We therefore spiked the 
pooled serum samples of healthy individuals with reference DNA for our studies, to 
achieve levels of CFDNA comparable to those reported in cancer patients [10]. 
 
A number of different methods have been used to quantify CFDNA, including DNA 
dipsticks, the PicoGreen double-stranded DNA assay, dot-hybridization or nick 
translation [10].  More recently, quantitative real-time PCR (QPCR) methods have 
been widely used including SYBR green, Taqman and allele specific real time PCR.  
These methods have varying specificity and sensitivity [22].  Here we chose to use 
the PicoGreen and SYBR green assays to combine adequate sensitivity within the 
expected concentration range, with robust and easily optimised assays. 
 
Although the QIAamp blood kit is the most popular method for extracting CFDNA, it 
does not appear very efficient at such low DNA concentrations. We sought to 
increase its efficiency by pre-incubating samples with a different protease to remove 
proteins. Proteinase K is a subtilisin-type protease particularly suitable for short 
digestion times. The predominant site of cleavage is the peptide bond adjacent to the 
carboxyl group of aliphatic and aromatic amino acids with blocked alpha amino 
groups. Raising the temperature of proteinase K from 37oC to 50-60oC can increase 
its activity several fold [23]. We found that proteinase K was more efficient than 
QIAgen protease, and that incubation at 37oC gave better results than RT or 50oC on 
CFDNA purification. One potential explanation is that higher temperature and longer 
incubation times accelerate DNA degradation or fragmentation and its impact cannot 
be made up by the increased activity of protease.  We also tested another SDS-
containing buffer recommended by Schmidt et al [20], but discovered that molecular 
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grade SDS from several manufacturers is contaminated with variable amounts of 
DNA (results not shown).  Hence this method cannot be recommended for the 
extraction of CFDNA.   
 
We studied the effects of varying the type, temperature and volume of elution buffer 
in the QIAamp protocol. Some authors use small volumes of elution buffer (50µl) to 
obtain a concentrated DNA solution for subsequent PCR analysis [24, 26].  However, 
we found that using low volumes of elution buffer led to a significantly lower DNA 
yield. The yield could be significantly improved by eluting twice using two volumes of 
200µl and 100µl, successively.  However, the dilution in 300µl might have rendered 
low CFDNA concentrations undetectable, leading to false-negative PCR results. We 
found no obvious difference when using distilled water or AE buffer, at RT or 40oC. 
Because buffer AE has the potential to inhibit PCR reactions, sterile distilled water is 
preferred as elution buffer [27].  
 
In the THP protocol, 98oC incubation was used to inactivate PCR inhibitors and 
denature proteins in plasma/serum samples. Different times and temperatures were 
tested before choosing this.  Since we had noticed substantial DNA contamination in 
SDS, Triton X-100 was used in the protein solubilization step. Direct conventional 
PCR was performed successfully on heat-denatured samples and able to detect 25 
ng/ml DNA, indicating that this simple procedure offered sufficient protein digestion 
and inhibitor elimination for PCR analysis. The THP protocol gave a significantly 
higher yield of pure DNA solution for qPCR analysis than the QIAamp kit. The THP 
protocol showed high efficiency even with small DNA fragments as low as 100 bp. 
The abilities of these protocols to extract the CFDNA were evaluated by quantitive 
12 
PCR. This showed that the THP products were more reproducible and consistent 
than the standard QIAamp protocol. In addition it is simple, relatively cheap and easy 
to perform and standardise. Phenol can present risks to the user, including burns on 
contact with the skin or mucous membranes, and carcinogenicity.  It is therefore 
important to adhere to stringent protocols for its safe use in the laboratory.  However, 
laboratory staff working with very low levels of DNA in human plasma and serum 
samples are familiar with careful procedures to avoid contamination of samples, and 
the risk of spillages in this setting is low. 
 
The way clinical blood samples are handled before reaching the laboratory has 
significant impact on CFDNA yields. These findings will therefore be important in 
designing our future clinical studies. We found that recovered CFDNA from blood 
samples kept at RT was comparable to the samples on ice processed at same time 
intervals (0 to 25 hours), which is consistent with other observations [27, 28]. 
However, delays in separating the plasma could increase the amount of recovered 
DNA. This contradicts the observations of Jung et al [28], who reported that the DNA 
concentration in plasma did not change when blood samples were stored at RT for 8 
h, or at 4oC for 24 h. These contradictory results might be due to sampling at only 
two time points (8 and 24 h) at 4oC in their study. It is likely that the increased DNA 
levels found at 25h are attributable to contamination of plasma with genomic DNA 
from leukocyte lysis [3].  
 
In summary, we recommend that blood samples for CFDNA analysis are collected 
into EDTA tubes and held at/or below RT (18oC – 22oC) for no more than 2 hours 
before separation of plasma. Plasma should be separated from whole blood samples 
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by double centrifugation (800g and 1,600g for 10 minutes, separately), avoiding 
leukocyte lysis. We prefer to isolate CFDNA immediately after plasma separation to 
minimize the effect of prolonged storage. Otherwise, samples should be aliquoted 
into small portions and stored at –70oC before extraction because fragmentation of 
CFDNA might be caused by repeated freeze-thaw cycles. Because of its higher 
efficiency, low-cost, easy-of-handling and good quality products for PCR analysis, we 
recommend the THP method for CFDNA extraction from limited clinical samples. The 
simplicity of the THP protocol should facilitate the genetic analysis of large 
populations. Of importance, the details of pre-analytic factors like sample collection 
and processing time should be specified in study protocols and taken into account 
during data analysis. We are now using this methodology in a study of CFDNA from 
lung cancer patients and controls.   
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Figure 1. Effects of different protease and incubation conditions on CFDNA 
yield. 
Pooled human serum samples spiked with reference DNA (final concentration: 100 
ng/ml) were pre-incubated with the QIAgen protease = Q (□) and proteinase K = P 
(■) for 1 hour at 370C or 500C prior to QIAamp DNA extraction. Results are shown as 
box plots for 5 replicates. The upper and lower limits of the boxes and the line across 
the boxes indicate the 90th and 10th percentiles and the mean, respectively. The 
upper and lower horizontal bars indicate the max and min. Standard: DNA extraction 
was processed according to the “blood and body fluid” protocol (no incubation time 
and 200 μl of elution buffer).  
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Figure 2. Effects of different volume of elution buffer on CFDNA yield. 
Pooled human serum samples spiked with reference DNA (final concentration: 100 
ng/ml) were pre-digested by proteinase K at 37oC for 1 hour, the DNA was isolated 
using the QIAamp DNA Midi Kit, then eluted in different volumes of buffer AE 
(provided in kit) from 50 μl (A) to 500 μl (F), in one or two aliquots, as indicated, 
columns were incubate 10 minutes at RT before centrifugation. Experiments were 
performed in 2 days and each day in 3 replicates. Data are presented as Mean (dot) 
± SD (error bar). Statistically differences were found between A and F (p < 0.001), B 
and F (p < 0.001), C and F (p < 0.001), while means of group D, E and F are not 
significantly different (D vs F, p=0.23; E vs F, p=0.18). 
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Figure 3. Utility of extracted CFDNA for genetic analysis. 
A. Efficiency of extraction of small DNA fragments. 
A 100bp-DNA ladder was spiked in pooled healthy human serum before DNA 
extraction by standard QIAamp (lane 1), modified QIAamp (lane 2) and THP (lane 3) 
protocols. The purified DNA was then analyzed on a 1.5% agarose gel. Marker = 
100-bp DNA ladder. Modified QIAamp protocol: proteinase K was applied instead of 
QIAgen protease with 1 hour incubation at 370C and 300 μl of ddH2O was used as 
elution buffer. 
B. Conventional PCR amplification of p53 gene in CFDNA purified by THP. 
Pooled human serum was spiked with 50 ng/ml (lane 1-3) and 200 ng/ml (lane 4-6) 
genomic DNA before THP extraction. The p53 gene primers were used to amplify a 
225-bp fragment. Marker = 100-bp DNA ladder; NTC = ddH2O (negative control). 
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Figure 4. SYBR-Green real-time PCR amplification curves for the hGAPDH gene 
in CFDNA. 
Pooled human serum CFDNA was extracted by (A) QIAamp or (B) THP. For both 
groups, CFDNA isolation was done in 5 replicates and each purified DNA sample 
was amplified in 3 replicates. 
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Figure 5. Comparison of two methods for the isolation of CFDNA. 
CFDNA was extracted from pooled human serum (reference DNA: linearized bcl-2 
plasmid DNA) using the THP procedure or the QIAamp standard protocol. DNA 
Extraction was performed in 20 replicates and each sample was quantified by SYBR-
Green real-time PCR in triplicate. Data are presented as scatter dot plot and the line 
indicates the Mean value. The coefficients of variation (CV) of the THP and QIAamp 
groups were 18.5% and 23.3%, respectively.  
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Figure 6. Effects of delays and storage temperature before plasma separation 
on CFDNA yield. 
Blood samples were collected in EDTA-vacutainer tubes and held at RT (■) or on ice 
(□). Plasma separation and DNA extraction were processed using THP protocol at 
different time intervals after venepuncture, as indicated. Experiments were performed 
in triplicate. The upper and lower limits of the boxes and the line across the boxes 
indicate the max and min values and the mean, respectively. 
 
